ASB-2 Inhibitors

Chemical inhibitors of ASB-2 function by obstructing the ubiquitin-proteasome system (UPS), which is essential for the degradation of proteins targeted by ASB-2. As ASB-2 mediates the ubiquitination of substrates for proteasomal degradation, inhibitors like MG132, Lactacystin, and Bortezomib directly impede the proteolytic activity of the 26S proteasome. MG132 achieves this by reversible inhibition, while Lactacystin and Bortezomib, the latter also known as Velcade, bind irreversibly to the catalytic site of the proteasome, blocking the degradation pathway necessary for ASB-2's function. Carfilzomib, Oprozomib, and Delanzomib are also proteasome inhibitors, with Carfilzomib and Delanzomib providing selective and irreversible binding. This action results in the accumulation of ubiquitinated proteins, thus negating the role of ASB-2 in targeting these proteins for degradation.

Further inhibiting ASB-2's function, Ixazomib and Marizomib, which is also known as Salinosporamide A, are small-molecule inhibitors that prevent the breakdown of ubiquitinated protein substrates by the proteasome. Marizomib is particularly potent due to its ability to cross the blood-brain barrier, ensuring a wide range of inhibition. Epoxomicin, another natural product, disrupts proteasome activity by irreversibly binding to it, leading to a build-up of proteins tagged by ASB-2, effectively inhibiting the protein's role in ubiquitin-mediated proteolysis. Lastly, ONX 0914 targets the immunoproteasome, specifically the LMP7 subunit, which can indirectly inhibit ASB-2 by impeding the degradation of immune-related proteins that ASB-2 may mark for ubiquitination. The collective action of these proteasome inhibitors results in a functional blockade of ASB-2's ability to facilitate the degradation of its protein targets, thereby impeding the protein's overall function within the UPS.